# Alkermes plc (ALKS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $7.40B  
**Price:** $43.84 (-1.02%)

> Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.48B | $1.28B | $254M | $242M | — |
| 2024 | $1.56B | $1.31B | $421M | $367M | — |
| 2023 | $1.66B | $1.41B | $414M | $356M | — |
| 2022 | $1.11B | $894M | -$6M | -$158M | — |
| 2021 | $1.17B | $976M | $98M | -$48M | — |
| 2020 | $1.04B | $860M | -$112M | -$111M | — |
| 2019 | $1.17B | $991M | -$175M | -$197M | — |
| 2018 | $1.09B | $918M | -$99M | -$139M | — |
| 2017 | $903M | $749M | -$148M | -$158M | — |
| 2016 | $746M | $614M | -$209M | -$208M | — |
| 2015 | $628M | $489M | -$224M | -$227M | — |
| 2014 | $619M | $443M | -$87M | -$30M | — |
| 2013 | $596M | — | $34M | — | — |
| 2013 | $576M | $405M | $82M | $25M | — |
| 2012 | $390M | $262M | -$88M | -$114M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.49B | $668M | $1.82B | $389M | — |
| 2024 | $2.06B | $591M | $1.46B | $291M | — |
| 2023 | $2.14B | $934M | $1.20B | $457M | $288M |
| 2022 | $1.96B | $920M | $1.04B | $292M | $290M |
| 2021 | $2.02B | $912M | $1.11B | $338M | $293M |
| 2020 | $1.95B | $883M | $1.07B | $273M | $272M |
| 2019 | $1.81B | $720M | $1.09B | $204M | $274M |
| 2018 | $1.83B | $654M | $1.17B | $267M | $276M |
| 2017 | $1.80B | $594M | $1.20B | $191M | $278M |
| 2016 | $1.73B | $517M | $1.21B | $186M | $284M |
| 2015 | $1.86B | $541M | $1.31B | $181M | $350M |
| 2014 | $1.92B | $522M | $1.40B | $224M | $356M |
| 2013 | $1.58B | $512M | $1.07B | $168M | $364M |
| 2013 | $1.47B | $518M | $952M | $97M | $369M |
| 2012 | $1.44B | $581M | $854M | $84M | $444M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $521M | $40M | $480M |
| 2024 | $439M | $33M | $406M |
| 2023 | $401M | $48M | $353M |
| 2022 | $21M | $38M | -$17M |
| 2021 | $102M | $28M | $74M |
| 2020 | $83M | $42M | $41M |
| 2019 | $72M | $91M | -$19M |
| 2018 | $99M | $69M | $30M |
| 2017 | $19M | $51M | -$32M |
| 2016 | -$64M | $44M | -$107M |
| 2015 | -$40M | $53M | -$93M |
| 2012 | -$2M | $17M | -$19M |
| 2011 | -$6M | $9M | -$15M |
| 2010 | -$12M | $16M | -$28M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ALKS)